Form 4: Singular Genomics CFO Dalen Meeter Reports Stock Transactions

Singular Genomics' Chief Financial Officer, Dalen Meeter, reported the acquisition of 209 shares of common stock through the settlement of vested Restricted Stock Units and also reported holding 9,002 shares of common stock.

Summary

• Dalen Meeter, the Chief Financial Officer of Singular Genomics Systems, Inc., filed a Form 4 detailing changes in his beneficial ownership of the company's stock.
• On December 15, 2024, Mr. Meeter acquired 209 shares of common stock through the settlement of vested Restricted Stock Units (RSUs).
• Each RSU represents a contingent right to receive one share of Singular Genomics' common stock.
• The reported transaction also includes 100 shares acquired under the company's employee stock purchase plan since the last Form 4 filing.
• Following these transactions, Mr. Meeter beneficially owns 9,002 shares of Singular Genomics common stock.
• Mr. Meeter also holds 1,874 Restricted Stock Units that vest quarterly over four years from March 15, 2023.

Sentiment

Score: 7

Explanation: The document reflects routine transactions by a company executive, which is generally neutral to positive. The increase in share ownership by the CFO can be seen as a positive sign of confidence in the company.

Positives

• The acquisition of shares through RSU vesting and the employee stock purchase plan indicates continued alignment of the CFO's interests with the company's performance.
• The increase in share ownership by a key executive can be seen as a positive sign of confidence in the company's future.

Industry Context

This filing is a routine disclosure of stock transactions by a company executive, which is common in publicly traded companies. It provides transparency into the ownership structure and alignment of management's interests with shareholders.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, and this filing is consistent with the requirements of the Securities and Exchange Commission.
• The vesting schedule of the Restricted Stock Units is typical for executive compensation packages in the biotechnology industry, with a four-year vesting period.

Stakeholder Impact

• The increase in share ownership by a key executive can be seen as a positive sign by shareholders.
• The transactions do not have a direct impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Singular Genomics, Dalen Meeter, Form 4, Beneficial Ownership, Restricted Stock Units, RSU, Stock Transactions, Employee Stock Purchase Plan, SEC Filing